Fig. 7: Potential involvement of the SLAMF7/EAT-2 pathway activation in macrophages in the anti-high-risk neuroblastoma immune response.
From: Macrophage-mediated anti-tumor immunity against high-risk neuroblastoma
A Cohort 1: (a) The expression of SLAMF7, encoding a macrophage activating receptor was detected in high-risk neuroblastomas of Cohort 1. (b) High SLAMF7 expression was associated with better survival of high-risk neuroblastoma patients. Similar observations were made for SH2D1B, encoding the obligatory activating signal transduction molecule EAT-2 (c, d). The housekeeping gene TBP was used as a reference. The expression unit of genes in Cohort 1 is Reads Per Million (RPM). B Cohort 2: the SLAMF7/EAT-2 pathway in macrophages in high-risk neuroblastomas of Cohort 2. The expression of SLAMF7 and SH2D1B was detected in high-risk neuroblastoma tissues of Cohort 2 (a, c). High expressions of both SLAMF7 and SH2D1B were associated with better survival of high-risk neuroblastoma patients of Cohort 2 (b, d). The custom algorithm was used to normalize the expression level of genes in Cohort 2, and therefore no formal unit applied to the expression level. C (a) SLAMF7 and SH2D1B expressions were highly correlated with each other. (b) Patients having high-risk neuroblastoma with high expression of both SLAMF7 and SH2D1B exhibited better survival. Cohort 1 was used in the analysis. The expression unit of genes in Cohort 1 is Reads Per Million (RPM).
